Allena Pharmaceuticals, Inc. Goodwill and Intangible Assets (Total)

Goodwill and Intangible Assets (Total) of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Goodwill and Intangible Assets (Total) growth rates and interactive chart. The sum of goodwill and all other intangible assets. Intangible assets are items that a company owns and derives benefit from, but is unable to physically measure and count. Examples of intangible assets include patents, trademarks and copyrights. Goodwill is a special type of intangible asset that normally appears in a company's balance sheet following a business combination. When the fair value of the consideration paid by the purchaser for an entity exceeds the fair value of the net assets they have acquired, the purchaser must recognize the resulting difference as goodwill in their balance sheet.


Highlights and Quick Summary

  • Goodwill and Intangible Assets (Total) for the quarter ending June 30, 2017 was $0 (a NaN% decrease compared to previous quarter)
  • Year-over-year quarterly Goodwill and Intangible Assets (Total) decreased by NaN%
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Goodwill and Intangible Assets (Total) of Allena Pharmaceuticals, Inc.

Most recent Goodwill and Intangible Assets (Total)of ALNA including historical data for past 10 years.

Interactive Chart of Goodwill and Intangible Assets (Total) of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Goodwill and Intangible Assets (Total) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2017 $0.0 $0.0
2016 $0.0
2015 $0.0

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.